The relationship between heart attacks and oxygen therapy has undergone a major paradigm shift. For decades, every heart attack patient received supplemental oxygen as a matter of routine. Then the AVOID trial in 2015 showed that routine oxygen in heart attack patients with normal oxygen levels may actually increase heart damage. Current AHA and ESC guidelines now recommend oxygen only when blood oxygen saturation drops below 90%. This is one of the most significant reversals in emergency cardiac care in the last 20 years.
Supplemental oxygen during a heart attack seems like it should be an obvious benefit. The heart muscle is starved of blood flow during a myocardial infarction, so delivering more oxygen should help. This intuition guided clinical practice for over a century.
The problem is that intuition was wrong, at least for patients who are not hypoxemic.
Key Takeaways
- The AVOID trial (2015) changed everything: Routine high-flow oxygen in normoxemic heart attack patients was associated with increased myocardial injury and larger infarct size.
- The DETO2X-AMI trial (2017) confirmed no benefit from routine oxygen in over 6,600 patients with suspected MI and normal oxygen levels.
- Current guidelines recommend oxygen only when SpO2 drops below 90% (AHA) or 90% (ESC).
- Oxygen IS still critical when patients are hypoxemic. The change is about routine use, not about withholding oxygen from patients who need it.
- The proposed harm mechanism involves coronary vasoconstriction and increased production of reactive oxygen species in oxygen-rich environments.
The Old Paradigm: Oxygen for Everyone
For more than 100 years, supplemental oxygen was considered standard of care for anyone experiencing a heart attack. The reasoning seemed sound: a myocardial infarction occurs when a coronary artery becomes blocked, cutting off blood supply to a portion of the heart muscle. If the problem is oxygen deprivation, the solution should be more oxygen.
Emergency protocols worldwide called for high-flow oxygen (typically 8 to 15 L/min via face mask) to be administered to all patients with suspected acute myocardial infarction, regardless of their oxygen saturation level. Textbooks endorsed it. Guidelines recommended it. Paramedics applied it reflexively.
But no large randomized trial had ever tested whether this practice actually helped.
The AVOID Trial: A Turning Point
The Air Versus Oxygen in Myocardial Infarction (AVOID) study, published in Circulation in 2015, was the first major randomized controlled trial to challenge routine oxygen use in heart attacks.
Study Design
- Patients: 638 randomized, 441 with confirmed ST-elevation myocardial infarction (STEMI) analyzed
- Intervention: High-flow oxygen (8 L/min via face mask) versus no supplemental oxygen (room air)
- Inclusion: Patients with STEMI diagnosed on paramedic 12-lead ECG and oxygen saturation above 94%
- Primary endpoint: Infarct size measured by cardiac enzymes and cardiac MRI at 6 months
Results
The findings were striking:
- Routine oxygen did not reduce myocardial infarct size
- Routine oxygen did not improve patient hemodynamics or reported symptoms
- Creatine kinase levels (a marker of heart muscle damage) were significantly higher in the oxygen group
- Cardiac MRI at 6 months showed larger infarct size in patients who received oxygen
- There was a trend toward increased rate of recurrent myocardial infarction in the oxygen group
The study concluded that routine high-flow oxygen supplementation “may be accompanied by harm” in patients with uncomplicated acute myocardial infarction who are not hypoxemic (Stub et al., 2015. DOI: 10.1161/CIRCULATIONAHA.114.014494).
“The AVOID trial identified a signal for increased myocardial injury during uncomplicated acute myocardial infarction with the routine use of supplemental oxygen.”
The DETO2X-AMI Trial: Confirmation
Following the AVOID trial, the much larger DETO2X-AMI trial was conducted in Sweden. Published in the New England Journal of Medicine in 2017, it randomized 6,629 patients with suspected acute MI and oxygen saturation of 90% or higher to receive either supplemental oxygen (6 L/min for 6 to 12 hours) or ambient air.
The primary finding: oxygen therapy did not reduce one-year all-cause mortality (5.0% in the oxygen group versus 5.1% in the ambient air group). A subsequent cost-effectiveness analysis found that avoiding routine oxygen therapy saves significant healthcare expenditure without compromising patient outcomes.
Why Oxygen Can Harm During a Heart Attack
Several biological mechanisms explain why excess oxygen can worsen outcomes during a myocardial infarction:
- Coronary vasoconstriction: Hyperoxia (excess blood oxygen) causes coronary arteries to constrict. During a heart attack, when blood flow is already compromised, further constriction reduces blood delivery to the ischemic myocardium. Studies have shown that breathing high-concentration oxygen can reduce coronary blood flow by 10% to 30%.
- Reactive oxygen species (ROS): Excess oxygen generates free radicals that damage cardiac cells, particularly during reperfusion (when blood flow is restored after the artery is opened). This “reperfusion injury” can paradoxically worsen cell death in the area surrounding the infarct.
- Reduced cardiac output: Hyperoxia can decrease heart rate and cardiac output, which is counterproductive during an acute cardiac event.
- Absorption atelectasis: High-flow oxygen can displace nitrogen from the lungs, causing small airways to collapse. This can actually worsen oxygenation in some patients.
Current Guidelines
The AVOID and DETO2X-AMI trials prompted major guideline changes across the world:
| Organization | Recommendation |
|---|---|
| AHA/ACC (2020) | Supplemental oxygen should be administered when SpO2 < 90%. Routine oxygen is not recommended for patients with SpO2 >= 90%. |
| ESC (2023) | Oxygen supplementation is indicated when SpO2 < 90%. Routine oxygen in normoxemic patients is not recommended. |
| AAFP (2020) | Supplemental oxygen should not be routinely given to nonhypoxemic patients with acute coronary syndrome. |
| Australian Resuscitation Council | Target SpO2 of 93% to 96%. No routine oxygen for normoxemic patients. |
When Oxygen IS Still Needed
The paradigm shift is about routine use, not about abandoning oxygen therapy entirely. Oxygen remains critical in specific situations:
- Hypoxemia (SpO2 < 90%): Any heart attack patient whose blood oxygen drops below 90% should receive supplemental oxygen immediately. This is not controversial.
- Cardiogenic shock: Patients in shock with poor perfusion and respiratory distress need oxygen support.
- Heart failure with pulmonary edema: When fluid in the lungs impairs gas exchange, oxygen is essential.
- Cardiac arrest: High-flow oxygen is standard during and immediately after resuscitation.
- Respiratory distress: Any patient who is visibly struggling to breathe should receive oxygen regardless of SpO2 readings.
The key distinction is between targeted oxygen therapy (giving oxygen to patients who need it based on objective measurements) and routine oxygen therapy (giving oxygen to everyone with a heart attack regardless of their oxygen status).
What This Means for Patients
If you or someone you know is having a heart attack:
- Call emergency services immediately. Oxygen management is a clinical decision that paramedics and emergency physicians will handle.
- Do not refuse oxygen if paramedics offer it. They are trained to assess whether you need it based on your vital signs.
- Do not worry if you are not given oxygen. If your oxygen levels are normal, withholding supplemental oxygen is the current evidence-based standard of care. It is not negligence.
- If you have a home oxygen concentrator, do not start using it during a suspected heart attack without medical guidance.
Frequently Asked Questions
Does oxygen make heart attacks worse?
In patients with normal oxygen levels (SpO2 >= 90%), routine supplemental oxygen has been associated with increased heart muscle damage. It does not “make heart attacks worse” in the dramatic sense, but it can increase infarct size. In patients with low oxygen levels, oxygen is beneficial and necessary.
Why did doctors give oxygen to all heart attack patients for so long?
The practice was based on logical reasoning (more oxygen should help oxygen-starved heart tissue) and decades of clinical tradition. It was never tested in large randomized trials until the AVOID trial in 2015. This is a good example of how medical practice can persist for decades without being validated by rigorous evidence.
Should I still have supplemental oxygen available if I have heart disease?
If you have been prescribed home oxygen for a chronic condition (like COPD or chronic heart failure with hypoxemia), continue using it as directed. The new guidelines apply specifically to the acute treatment of myocardial infarction in the emergency setting, not to chronic oxygen prescriptions.
How do paramedics decide whether to give oxygen during a heart attack?
Paramedics now use pulse oximetry (a clip sensor on the finger) to measure blood oxygen saturation. If SpO2 is below 90% to 94% (depending on local protocols), they administer oxygen. If SpO2 is normal, they typically withhold supplemental oxygen and monitor closely.
References
- Stub, D., et al. (2015). Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation, 131(24), 2143-2150. DOI: 10.1161/CIRCULATIONAHA.114.014494
- Hofmann, R., et al. (2017). Oxygen therapy in suspected acute myocardial infarction. New England Journal of Medicine, 377(13), 1240-1249. DOI: 10.1056/NEJMoa1706222
- Hofmann, R., et al. (2022). Avoiding routine oxygen therapy in patients with myocardial infarction saves significant expenditure. Frontiers in Public Health, 9, 711222. DOI: 10.3389/fpubh.2021.711222
- Sepehrvand, N., et al. (2018). Oxygen therapy in patients with acute myocardial infarction: a systemic review and meta-analysis. American Journal of Medicine, 131(6), 693-701. DOI: 10.1016/j.amjmed.2017.12.027
- Khoshnood, A., et al. (2018). Oxygen therapy for acute myocardial infarction. Medical Gas Research, 8(4), 155-159.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
